Prothena Corp (PRTA)

Dec 30, 2024, 4:05 PM EST - 19 days ago

Prothena Announces Board of Directors Update

Dec 19, 2024, 1:05 AM EST - 4 weeks ago

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Nov 12, 2024, 4:05 PM EST - 2 months ago

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 5, 2024, 4:05 PM EST - 2 months ago

Prothena to Report Third Quarter 2024 Financial Results on November 12

Sep 27, 2024, 4:05 PM EDT - 4 months ago

Prothena Announces Leadership Team Updates

Aug 29, 2024, 4:05 PM EDT - 5 months ago

Prothena to Participate in Upcoming Healthcare Conferences

Aug 8, 2024, 4:05 PM EDT - 5 months ago

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 1, 2024, 4:05 PM EDT - 6 months ago

Prothena to Report Second Quarter 2024 Financial Results on August 8

May 28, 2024, 4:05 PM EDT - 8 months ago

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

May 8, 2024, 4:05 PM EDT - 9 months ago

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

May 1, 2024, 4:05 PM EDT - 9 months ago

Prothena to Report First Quarter 2024 Financial Results on May 8

Apr 15, 2024, 4:05 PM EDT - 9 months ago

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Mar 4, 2024, 4:05 PM EST - 11 months ago

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Feb 23, 2024, 12:31 PM EST - 11 months ago

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Feb 21, 2024, 4:05 PM EST - 11 months ago

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Feb 15, 2024, 11:53 PM EST - 1 year ago

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 4:05 PM EST - 1 year ago

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 8, 2024, 4:05 PM EST - 1 year ago

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Jan 8, 2024, 8:30 AM EST - 1 year ago

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 26, 2023, 4:05 PM EDT - 1 year ago

Prothena to Report Third Quarter 2023 Financial Results on November 2

Oct 16, 2023, 11:57 AM EDT - 1 year ago

Prothena prepares for potential sale - Bloomberg News

Sep 21, 2023, 1:39 PM EDT - 1 year ago

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Aug 3, 2023, 4:05 PM EDT - 1 year ago

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Jul 27, 2023, 4:05 PM EDT - 1 year ago

Prothena to Report Second Quarter 2023 Financial Results on August 3

Jul 27, 2023, 7:23 AM EDT - 1 year ago

Prothena: Dunn Appointment And Bristol Opt-In Boost Validation

Jul 17, 2023, 8:35 AM EDT - 1 year ago

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 11, 2023, 4:05 PM EDT - 1 year ago

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 10, 2023, 4:10 PM EDT - 1 year ago

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

Jun 27, 2023, 4:05 PM EDT - 1 year ago

Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab

Jun 2, 2023, 4:05 PM EDT - 1 year ago

Prothena to Participate in Jefferies 2023 Healthcare Conference

May 16, 2023, 4:05 PM EDT - 1 year ago

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors

May 7, 2023, 2:28 AM EDT - 1 year ago

Prothena Biosciences' Unique Approach To Protein Misfolding Could Be The Future

May 4, 2023, 4:05 PM EDT - 1 year ago

Prothena Reports First Quarter 2023 Financial Results and Business Highlights

Apr 27, 2023, 4:05 PM EDT - 1 year ago

Prothena to Report First Quarter 2023 Financial Results on May 4

Apr 24, 2023, 4:05 PM EDT - 1 year ago

Prothena to Participate in 2023 Bank of America Healthcare Conference

Apr 13, 2023, 8:00 AM EDT - 1 year ago

Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer's Disease Clinical Trial

WBA

Mar 31, 2023, 9:20 AM EDT - 1 year ago

Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

Mar 21, 2023, 4:05 PM EDT - 1 year ago

Prothena to Participate in Stifel 2023 Virtual CNS Days

Mar 14, 2023, 4:05 PM EDT - 2 years ago

Prothena to Highlight Next Generation Treatments for Alzheimer's and Parkinson's Disease at the AD/PD 2023 Meeting

Feb 24, 2023, 12:33 AM EST - 2 years ago

Prothena Corporation plc (PRTA) Q4 2022 Earnings Call Transcript

Feb 23, 2023, 4:05 PM EST - 2 years ago

Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 16, 2023, 4:05 PM EST - 2 years ago

Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

Feb 3, 2023, 4:05 PM EST - 2 years ago

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 31, 2023, 4:05 PM EST - 2 years ago

Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer's Disease

Dec 14, 2022, 10:38 PM EST - 2 years ago

Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares

Dec 13, 2022, 4:12 PM EST - 2 years ago

Prothena Announces Proposed Public Offering of Ordinary Shares

Dec 12, 2022, 11:30 AM EST - 2 years ago

Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022

Nov 21, 2022, 4:05 PM EST - 2 years ago

Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy

Nov 3, 2022, 4:05 PM EDT - 2 years ago

Prothena Reports Third Quarter 2022 Financial Results and Business Highlights